

TIM3 Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
TIM3 Concentrate	FP-A049-01	0.1 ml
TIM3 Concentrate	FP-A049-10	1 ml
TIM3 Predilute	FP-A049-70	7 ml

Description

T-cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumor-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.

Specifications

Clone	IHC003
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Tonsil
Dilution Range	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the corresponding user manual for detection system

*Result should be confirmed by an established diagnostic procedure.

Result




Figure TIM3 on Kidney



Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

The product is for research use only. Do not use for diagnosis purpose. Ensure proper handling procedures are used with all reagents. Always wear laboratory coats, disposable gloves, and other appropriate laboratory equipment when handling reagents. Do not ingest reagents, and avoid contact with eyes and mucous membranes. Wash eyes with copious amounts of water if contact occurs.

References

1. Monney L, et al. Nature. 2002; 415:536-41.
2. Sánchez-Fueyo A, et al. Nat Immunol. 2003; 4:1093-101.
3. Anderson AC. Cancer Immun Res. 2014; 2:393–8.
4. Gao X, et al. PLoS One. 2012; 7:e30676.

Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for assistance with more questions regarding this product.